Status of generic substitution: problematic drug classes reviewed

Area of Science:

• Pharmacoeconomics
• Drug Efficacy and Safety
• Regulatory Science

Background:

• The Drug Price Competition and Patent Term Restoration Act of 1984 facilitated generic drug market entry.
• Generic drugs must meet Food and Drug Administration (FDA) standards for bioequivalence and quality.
• Despite regulations, reports of inequivalence and lack of efficacy exist for both generic and brand-name drugs.

Purpose of the Study:

• To review current data comparing brand-name and generic drug products for specific problematic drug classes.
• To explain terminology related to brand-name and generic drugs.
• To discuss legislative changes and recommend actions for medication-related problems.

Main Methods:

• Literature review of current data on brand-name versus generic drug products.
• Analysis of problematic drug classes including thyroid preparations, conjugated estrogens, digoxin, phenothiazines, theophylline, and anticonvulsants.
• Review of relevant legislation and recommendations for addressing medication issues.

Main Results:

• Data on the comparative efficacy and equivalence of brand-name and generic drugs are presented for selected drug classes.
• Inequivalence and efficacy issues have been documented for both generic and brand-name medications.
• The article provides definitions of key terms and discusses legislative updates.

Conclusions:

• While generic drugs are held to high standards, ongoing evaluation of their equivalence and efficacy is crucial.
• Brand-name drugs also present challenges regarding efficacy and equivalence.
• Recommendations are provided for healthcare professionals and regulatory bodies to address medication problems.